# BioLife Solutions, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BioLife Solutions, Inc). ## Overview BioLife Solutions Inc. is a U.S.-based life sciences company focused on bioproduction tools and services for the cell and gene therapy industry. It develops, manufactures, and markets products designed to preserve the health and function of biologic material during sourcing, manufacturing, storage, and transport. The company’s portfolio centers on biopreservation media, cell processing products, and automated thawing and handling devices used in research and commercial manufacturing. BioLife has also used acquisitions and divestitures to sharpen its focus on the core bioproduction workflow. Its business model is tied to the growth of commercial cell and gene therapies, where product reliability and handling quality are critical. ## Products & services • Biopreservation media for cells and tissues • Human platelet lysate (hPL) media • Cryogenic and ultralow-temperature containers • Automated cell-processing fill machines • ThawSTAR automated thawing devices • Cloud-connected smart shipping containers - **Biopreservation media** (55%) — Specialized media used to maintain viability and function of biologic material during sourcing, processing, storage, and transport. - **Cell processing products** (20%) — Tools such as hPL media, cryogenic containers, and fill machines used in cell handling and manufacturing workflows. - **Automated thawing devices** (10%) — ThawSTAR devices and related systems that standardize thawing of biologic materials before use. - **Shipping and temperature-control solutions** (10%) — Smart shipping containers and cold-chain products used to protect biologic materials in transit. - **Services and technical support** (5%) — Application support, customer care, and technical services that help customers implement and use the products. - Biopreservation media for cell and gene therapy workflows - Human platelet lysate media for cell culture and processing - Cryogenic and ultralow-temperature containers - Automated cell-processing fill machines - ThawSTAR automated thawing devices - Cloud-connected smart shipping containers - Bioproduction tools and services for biologic transport ## Customers BioLife sells primarily to cell and gene therapy developers, biopharma manufacturers, and research organizations that need to preserve biologic material with high reliability. Customers buy its products to reduce process risk, improve yield, and maintain cell viability during manufacturing and distribution. The company also serves commercial therapy customers, which is important because recurring demand tends to rise as therapies move from development into approved and scaled production. A meaningful portion of sales is routed through third-party distributors, which broadens reach into regional markets and smaller accounts. The customer base is specialized and technical, so scientific support and workflow integration are part of the buying decision, not just product price. - **Cell and gene therapy developers** (primary) — Buy biopreservation media and processing tools to protect cells during development, scale-up, and clinical manufacturing. - **Commercial biopharma manufacturers** (primary) — Purchase recurring consumables and workflow products to support approved therapies and commercial production. - **Research institutions and applied research labs** (secondary) — Use the company’s media and handling products for basic and translational research involving biologic materials. - **Third-party distributors** (secondary) — Resell the company’s products in regional markets and help extend commercial reach without direct local infrastructure. - Cell and gene therapy developers buying preservation tools for R&D and scale-up - Commercial biopharma manufacturers needing reliable biologic handling products - Research labs using biopreservation media and cell-processing products - Distributors that resell products into regional life-science markets - Customers seeking to reduce viability loss, contamination risk, and process variability - Therapy manufacturers needing standardized thawing and cold-chain handling ## Geography BioLife is headquartered in Bothell, Washington and operates as a U.S.-based company with sales to customers located by geography rather than by manufacturing footprint disclosed in the excerpts. The company’s revenue disclosure references customer location, but the provided excerpts do not include a country-by-country revenue table. Its business is exposed to global biopharma and cell-therapy demand because products are used in international manufacturing and distribution workflows. The use of third-party distributors also suggests a broader international commercial footprint than direct sales alone. Geography matters because biologic materials are time- and temperature-sensitive, so local service, shipping reliability, and regulatory access can affect adoption. - Headquartered in Bothell, Washington, United States - Revenue is generated from customers located across multiple markets - Third-party distributors extend reach into regional life-science markets - Products support global cell and gene therapy manufacturing workflows - No country-level revenue split was disclosed in the provided excerpts ## Strategy BioLife’s strategy is to concentrate on the bioproduction workflow for cell and gene therapy and expand the value of its core product platforms. Management emphasizes organic innovation, partnerships, and acquisitions as ways to broaden the portfolio and deepen customer relationships. The company also uses direct sales plus distributors to scale market access while keeping technical support close to the customer. Recent divestitures indicate a sharper focus on the core biopreservation and cell-processing business rather than a broader collection of adjacent assets. This strategy matters because the company competes on workflow relevance, product reliability, and scientific credibility in a highly specialized market. - **Deepen the core CGT workflow portfolio** (medium-term) — The company’s competitive position depends on being embedded in the customer’s biologic manufacturing process. - **Drive organic product innovation** (medium-term) — New products can increase wallet share and improve customer retention in a specialized market. - **Use acquisitions and partnerships selectively** (medium-term) — Adjacencies can extend the platform and add capabilities without building everything internally. - **Maintain technical sales and support capability** (short-term) — Customers buy based on performance, application fit, and support quality, not just product specs. - Focus on core biopreservation and cell-processing products - Expand through organic product innovation - Use partnerships and acquisitions to add workflow value - Support customers with technical applications and customer care - Leverage direct sales and distributors to broaden market access - Prune non-core businesses through divestitures ## Risks BioLife faces product-performance and technology-risk exposure because its products are used in sensitive biologic workflows where failures can damage customer outcomes and reputation. Demand is tied to the health of the cell and gene therapy market, so funding cycles, customer inventory destocking, and broader biotech sentiment can affect sales. The company also depends on manufacturing continuity and supply availability, making it vulnerable to disruptions in its own facilities or those of third-party suppliers. Public health crises, staffing shortages, and shipping delays can interrupt operations and customer access, which is especially important for temperature-sensitive products. As a specialized life-sciences supplier, it also faces product liability, recall risk, and the need to retain scientific and technical talent. - **Product reliability and technology acceptance** [high] — Customers rely on the products to preserve biologic material, so defects or doubts about performance can directly reduce sales and trust. - **Biotech funding and customer inventory cycles** [high] — The company’s demand is linked to cell and gene therapy spending, which can fluctuate with funding conditions and destocking. - **Manufacturing and supply-chain disruption** [medium] — Facility shutdowns or component shortages can delay shipments and reduce revenue recognition timing. - **Public health crisis disruption** [medium] — Pandemics or epidemics can affect workforce availability, logistics, and customer access. - **Product liability and recall exposure** [high] — Failures in products used in biologic manufacturing can create claims, remediation costs, and reputational damage. - **Key personnel retention** [medium] — The business depends on scientific, engineering, and sales expertise to support customers and develop products. - Product performance failures could reduce adoption and damage reputation - CGT market demand can weaken when biotech funding or customer inventories soften - Supply-chain disruptions can interrupt manufacturing and product availability - Public health events can close facilities, reduce staffing, and delay shipments - Product liability or recall events could create legal and remediation costs - Loss of key scientific and sales personnel could slow growth execution ## Accounting BioLife’s most important accounting judgments center on revenue recognition for product and service contracts under ASC 606, where timing depends on when performance obligations are satisfied. Revenue can also be affected by distributor arrangements and by the mix of consumables versus devices and services, which may have different recognition patterns. The company has had significant divestitures and acquisitions, so investors should watch discontinued operations accounting, transaction-related gains or losses, and any purchase accounting for acquired intangible assets or in-process R&D. Cash and investment balances include available-for-sale securities, which introduces fair-value measurement and unrealized gain/loss considerations. Because the business is tied to specialized products and customer demand can vary with biotech funding, quarterly revenue can be uneven and comparability across periods may be affected by order timing and inventory destocking. - **Revenue recognition** — Quarterly and annual revenue comparability - **Discontinued operations** — Reported revenue, operating income, and cash flow presentation - **Purchase accounting and intangible assets** — Amortization expense and future impairment charges - **Fair value of available-for-sale securities** — Balance sheet and equity volatility - Revenue recognition under ASC 606 affects when product and service sales are recorded - Distributor sales can change gross-to-net presentation and timing of revenue - Product mix between consumables and devices can affect margin and recognition patterns - Divestitures create discontinued operations accounting and one-time transaction effects - Acquisitions can create goodwill and intangible asset valuation judgments - Available-for-sale securities require fair-value and unrealized gain/loss accounting - Quarterly revenue can fluctuate with biotech funding cycles and customer destocking --- *Last updated: 2026-08-11T04:46:22.659877+00:00*